Abstract 370P
Background
LYMPHA is a relatively new surgical technique that dramatically reduces the incidence of lymphedema following axillary node clearance in breast cancer patients. The technique identifies dominant lymph vessels draining the arm with the aid of dye and, following clearance of the axillary nodes, anastomosing lymphatic vessels to a branch of the axillary vein to enable free drainage of lymphatic fluid. Not currently widely available to breast cancer patients in the UK, this simple surgical procedure carried out at the time of axillary node clearance has been shown to reduce the incidence of lymphedema from 25% to 4%. We report on the establishment of a LYMPHA service at a major London Plastics Centre and first 2 years of its outcomes.
Methods
Suitable patients were referred to plastics by the breast surgery team and seen preoperatively to discuss LYMPHA. Upon agreeing to the procedure, pre-operative measurements of arm volume and arm bioimpedance were completed as well as screening questionnaires on symptoms of lymphedema. Subsequent to the procedure the two measurements and the questionnaires were repeated at 1, 3, 6, 12 and 24 month intervals.
Results
Of 16 patients that have undergone the LYMPHA procedure 0 have experienced signs or symptoms of lymphedema to date. One patient suffered temporary swelling of the arm 1-month post-op which subsequently resolved. No patients have suffered any complications relating to LYMPHA. 1 patient withdrew due to metastatic disease recurrence. The patients enrolled have been followed up for between 3-23 months with a current mean follow up time of 12.61 months.
Conclusions
Our findings thus far support current evidence that LYMPHA surgery is both safe and effective in reducing the incidence of lymphedema. This pilot study is currently being developed into an RCT which will add to the evidence base of this relatively niche area of plastic surgery.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
434P - Incidence and prognostic value of HER2-low expression metastatic breast cancer in Asian population: A 10-year retrospective study
Presenter: Thanate Dajsakdipon
Session: Poster session 03
435P - Phase II single arm study of durvalumab and olaparib (D+O) in heavily pretreated triple-negative breast cancer (TNBC) with or without germline BRCA mutation (gBRCAm)
Presenter: Takeo Fujii
Session: Poster session 03
436P - Preliminary results from a prospective study of inetetamab in combination with pyrotinib and utidelone for HER2-positive metastatic breast cancer (IPUtrial)
Presenter: Hui Cao
Session: Poster session 03
437P - Improving safety and convenience for breast cancer patients receiving CDK 4/6 inhibitor treatment via a telemedicine app
Presenter: Bela Mrinakova
Session: Poster session 03
438P - Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+ advanced solid tumors
Presenter: Fengjuan Lin
Session: Poster session 03
439P - Testing HR+ / HER2- patients with advanced or metastatic breast cancer for identification of tissue mutations in the PIK3CA gene: Results of a national program by the Hellenic Society of Medical Oncology (HeSMO)
Presenter: Anastasios Boutis
Session: Poster session 03
440P - Palliative radiotherapy in metastatic breast cancer: Does molecular subtype predict patient response to radiotherapy?
Presenter: Meriem El Bessi
Session: Poster session 03
441P - Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL) in subgroups of special interest: 5th interim analysis (IA) of the RIBANNA study
Presenter: Achim Woeckel
Session: Poster session 03
442P - Menopausal status may derive in different second-line treatment benefits in breast cancer patients that experienced disease progression with CDK4/6 inhibitors (SUMA-001)
Presenter: Federico Waisberg
Session: Poster session 03
443P - Efficacy and safety of CDK 4/6 inhibitors in patients with bone marrow-involved metastatic breast cancer
Presenter: Cengiz Karacin
Session: Poster session 03